Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565308 | 0.85 | ACE (0.57) | ACEOPRM1OPRD1MMECPA1 | |
| SCHEMBL10617891 | 0.85 | ACE (0.59) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL10617903 | 0.85 | ACE (0.59) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL11598550 | 0.85 | ACE (0.48) | ACEMMECPA1ACE2ANPEP | |
| SCHEMBL28445731 | 0.84 | CTSD (0.46) | ACEOPRM1OPRD1MMECPA1 | |
| SCHEMBL27788518 | 0.84 | CTSC (0.57) | ACEMMECPA1ACE2CTSC | |
| SCHEMBL30832636 | 0.84 | ACE (0.53) | ACEOPRM1OPRD1MMECPA1 | |
| SCHEMBL16468891 | 0.83 | CTSD (0.46) | ACEMMECPA1ACE2CTSC | |
| SCHEMBL2183397 | 0.82 | ALDH1A1 (0.43) | OPRM1OPRD1MMEOPRK1CTSC | |
| SCHEMBL8936979 | 0.81 | OPRD1 (0.49) | ACEOPRM1OPRD1MMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | HTR3A, HNMT, HTR3B | ACE 2124/4885OPRM1 311/4885OPRD1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.